Centogene N.V. (CNTG) has released an update.
Centogene N.V. reported a modest 2% increase in total revenue for FY2023, reaching €48.5 million, and anticipates a stronger performance with projected growth of 10-15% in 2024. The company has fortified its cash position by securing approximately $20 million, partly through expanding its partnership with Lifera. Despite a net loss increase and a dip in Pharma segment revenues, Centogene remains optimistic with strategic collaborations and a robust diagnostics demand paving the way for future profitability.
For further insights into CNTG stock, check out TipRanks’ Stock Analysis page.
